He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over previous attempts of using CAR-T against brain cancers.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
​
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
​
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
​
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A
.png){kind=logo}
